Plain-English translation of NCT07254091 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Pancreatic Cancer research guide →Phase 1 — Testing in a small group (usually 20–80 people) to find a safe dose and watch for side effects.
This is an early-stage study testing a new miniature medical device that can be implanted directly into pancreatic tumors during surgery. The device stays in the tumor for about 4 hours while it's exposed to chemotherapy drugs, then is removed with the tumor specimen. Researchers want to see if this device can help predict whether a specific patient's cancer will respond well to treatment.
Pancreatic cancer is difficult to treat, and doctors don't have a reliable way to know in advance which chemotherapy drugs will work best for each patient. This study explores whether the device can provide real, personalized information about drug response directly from a patient's own tumor, which could help tailor future treatment decisions.
You likely qualify if…
You likely don't qualify if…
If you enroll, the study would be part of your pancreatic cancer surgery. During your operation, the surgeon will place the tiny device directly into your tumor, wait about 4 hours, and then remove it along with the tumor itself during your standard surgical resection. After surgery, you will be monitored closely for one month to make sure the device placement and removal didn't cause any unexpected complications. Tissue samples from around the device will then be studied in the laboratory.
AI-generated summary from trial data · Jun 10, 2026 · Not medical advice
United States